Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The STEP (Semaglutide Treatment Effect in People with obesity) trial program showed average weight reductions of approximately 15% of initial body weight over 68 weeks in individuals without diabetes, with somewhat lower reductions (about 9-10%) in those with type 2 diabetes
Contraindicated in patients with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia Syndromes (MEN 2) Not suitable for individuals with type 1 diabetes or diabetic ketoacidosis Should not be used alongside other GLP-1 receptor medications Gastric emptying may be delayed, requiring caution for procedures involving sedation or general anesthesia due to aspiration risk Use caution in those with a history of diabetic retinopathy 1-3 Consult your healthcare provider if you have a history of pancreatitis, as the medication may increase risk Serious side effects may involve hypoglycemia, kidney issues, or allergic reactions Avoid use during pregnancy and breastfeeding 1 Enhances glucose-dependent insulin secretion Suppresses glucagon secretion Slows gastric emptying Influences brain regions involved in appetite regulation, leading to reduced hunger and caloric intake Improves insulin sensitivity 1-3 Supports weight loss Helps to minimize internal inflammation and improves cardiometabolic health measures 5 Q: How long does it take to see results
9
Peer-reviewed clinical data showed that when consumed in sports drinks, KOHJINs OPITAC was able to replenish GSH levels more quickly and more easily digestible than other formulations, resulting in better performance and higher endurance
